Comparative Pharmacology
Head-to-head clinical analysis: SULFACETAMIDE SODIUM versus TRYSUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACETAMIDE SODIUM versus TRYSUL.
SULFACETAMIDE SODIUM vs TRYSUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitively inhibits dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Trypanocidal agent; forms a complex with DNA and inhibits nucleic acid synthesis.
1-2 drops of 10-30% solution into the conjunctival sac every 2-3 hours initially, tapering as infection resolves. Ointment: 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
2 tablets (each containing sulfamethoxazole 400 mg and trimethoprim 80 mg) orally every 12 hours for 10-14 days.
None Documented
None Documented
7-12.8 hours (prolonged in renal impairment; requires dosing adjustment in CrCl <50 mL/min).
Terminal elimination half-life: 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 85-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Renal: approximately 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: 15-20% as metabolites; small amount in feces.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic